C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -10.71% | 39.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.71% | 39.81% | |||
| Cost of Revenue | -3.23% | -16.73% | |||
| Gross Profit | 0.50% | 27.44% | |||
| SG&A Expenses | -6.03% | -10.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.95% | -15.12% | |||
| Operating Income | 2.27% | 22.66% | |||
| Income Before Tax | 1.15% | 23.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.15% | 23.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.15% | 23.87% | |||
| EBIT | 2.27% | 22.66% | |||
| EBITDA | 2.86% | 22.89% | |||
| EPS Basic | 1.40% | 24.12% | |||
| Normalized Basic EPS | -3.75% | 26.11% | |||
| EPS Diluted | 1.40% | 24.12% | |||
| Normalized Diluted EPS | -3.75% | 26.11% | |||
| Average Basic Shares Outstanding | 0.24% | 0.32% | |||
| Average Diluted Shares Outstanding | 0.24% | 0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||